Ascendis Pharma A/S

ISIN DK0060615755

 | 

WKN A42ANJ

Market cap (in EUR)
13,604 m
Country
Denmark
Sector
Healthcare
 

Overview

Description

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Denmark

Financials

Key metrics

Market capitalisation, EUR 13,604 m
EPS, EUR 11.89
P/B ratio 10.2
P/E ratio 18.4
Dividend yield -

Income statement (2025)

Revenue, EUR 720 m
Net income, EUR -228 m
Profit margin -31.67%

What ETF is Ascendis Pharma A/S in?

There are 5 ETFs which contain Ascendis Pharma A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Ascendis Pharma A/S is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 1.15%
Equity
United States
Health Care
Biotech
72
Vanguard Russell 1000 U.S. Value UCITS ETF USD Dist 0.00%
Equity
United States
Value
2
Goldman Sachs Alpha Enhanced World Equity Active UCITS ETF CLASS USD (Acc) 0.11%
Equity
World
Social/Environmental
303
Vanguard Russell U.S. Mid-Cap UCITS ETF USD Dist 0.10%
Equity
United States
Mid Cap
3
Amundi Prime Europe UCITS ETF DR (D) 0.08%
Equity
Europe
259
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.